<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.5//EN" "ep-patent-document-v1-5.dtd">
<ep-patent-document id="EP12717013B8W1" file="EP12717013W1B8.xml" lang="en" country="EP" doc-number="2699590" kind="B8" correction-code="W1" date-publ="20190417" status="c" dtd-version="ep-patent-document-v1-5">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>BDM Ver 0.1.63 (23 May 2017) -  2999001/0</B007EP></eptags></B000><B100><B110>2699590</B110><B120><B121>CORRECTED EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B8</B130><B132EP>B1</B132EP><B140><date>20190417</date></B140><B150><B151>W1</B151><B153>73</B153><B155><B1551>de</B1551><B1552>Bibliographie</B1552><B1551>en</B1551><B1552>Bibliography</B1552><B1551>fr</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>12717013.2</B210><B220><date>20120419</date></B220><B240><B241><date>20131120</date></B241><B242><date>20141118</date></B242></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>201161477585 P</B310><B320><date>20110420</date></B320><B330><ctry>US</ctry></B330></B300><B400><B405><date>20190417</date><bnum>201916</bnum></B405><B430><date>20140226</date><bnum>201409</bnum></B430><B450><date>20190220</date><bnum>201908</bnum></B450><B452EP><date>20180824</date></B452EP><B480><date>20190417</date><bnum>201916</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>A61K  38/00        20060101AFI20180727BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>ENDOGLINPOLYPEPTIDE UND IHRE VERWENDUNG</B542><B541>en</B541><B542>ENDOGLIN POLYPEPTIDES AND USES THEREOF</B542><B541>fr</B541><B542>POLYPEPTIDES D'ENDOGLINE ET LEURS UTILISATIONS</B542></B540><B560><B561><text>WO-A1-2007/143023</text></B561><B561><text>WO-A1-2008/151078</text></B561><B562><text>FRANCISCO J. BLANCO ET AL: "Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-[beta] receptor complex", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 204, no. 2, 1 August 2005 (2005-08-01), pages 574-584, XP055030607, ISSN: 0021-9541, DOI: 10.1002/jcp.20311</text></B562><B562><text>SCHARPFENECKER MARION ET AL: "BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis", JOURNAL OF CELL SCIENCE, vol. 120, no. 6, 1 March 2007 (2007-03-01) , pages 964-972, XP002490785, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB ISSN: 0021-9533, DOI: 10.1242/JCS.002949</text></B562><B562><text>R. CASTONGUAY ET AL: "Soluble Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor Growth", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 34, 26 August 2011 (2011-08-26), pages 30034-30046, XP055031457, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.260133</text></B562><B562><text>ALT AARON ET AL: "Structural and functional insights into endoglin ligand recognition and binding.", PLOS ONE, vol. 7, no. 2, E29948, 8 February 2012 (2012-02-08), pages 1-12, XP002679013, ISSN: 1932-6203</text></B562></B560></B500><B600><B620EP><parent><cdoc><dnum><anum>19150039.6</anum></dnum><date>20190102</date></cdoc></parent></B620EP></B600><B700><B720><B721><snm>GRINBERG, Asya</snm><adr><str>12468 Main Campus Drive</str><city>Lexington, MA 02421</city><ctry>US</ctry></adr></B721><B721><snm>CASTONGUAY, Roselyne</snm><adr><str>32 Grace Street</str><city>Malden, MA 02148</city><ctry>US</ctry></adr></B721><B721><snm>WERNER, Eric</snm><adr><str>68 Emerson Road</str><city>Milton, MA 02186</city><ctry>US</ctry></adr></B721><B721><snm>KUMAR, Ravindra</snm><adr><str>421 Arlington Street</str><city>Acton, MA 01720</city><ctry>US</ctry></adr></B721></B720><B730><B731><snm>Acceleron Pharma Inc.</snm><iid>101355326</iid><irf>E1427.502(F)EPW</irf><adr><str>128 Sidney Street</str><city>Cambridge, MA 02139</city><ctry>US</ctry></adr></B731></B730><B740><B741><snm>EIP</snm><iid>101401446</iid><adr><str>EIP Europe LLP 
Fairfax House 
15 Fulwood Place</str><city>London WC1V 6HU</city><ctry>GB</ctry></adr></B741></B740></B700><B800><B840><ctry>AL</ctry><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LT</ctry><ctry>LU</ctry><ctry>LV</ctry><ctry>MC</ctry><ctry>MK</ctry><ctry>MT</ctry><ctry>NL</ctry><ctry>NO</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>RS</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>SM</ctry><ctry>TR</ctry></B840><B860><B861><dnum><anum>US2012034295</anum></dnum><date>20120419</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2012145539</pnum></dnum><date>20121026</date><bnum>201243</bnum></B871></B870></B800></SDOBI>
</ep-patent-document>
